Titre : Inconduite professionnelle

Inconduite professionnelle : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inconduite professionnelle : Questions médicales les plus fréquentes", "headline": "Inconduite professionnelle : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inconduite professionnelle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-17", "dateModified": "2025-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inconduite professionnelle" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éthique", "url": "https://questionsmedicales.fr/mesh/D004989", "about": { "@type": "MedicalCondition", "name": "Éthique", "code": { "@type": "MedicalCode", "code": "D004989", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.350" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inconduite scientifique", "alternateName": "Scientific Misconduct", "url": "https://questionsmedicales.fr/mesh/D015871", "about": { "@type": "MedicalCondition", "name": "Inconduite scientifique", "code": { "@type": "MedicalCode", "code": "D015871", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.350.979.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Inconduite professionnelle", "alternateName": "Professional Misconduct", "code": { "@type": "MedicalCode", "code": "D028743", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Charles Piller", "url": "https://questionsmedicales.fr/author/Charles%20Piller", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Shokoh Varaei", "url": "https://questionsmedicales.fr/author/Shokoh%20Varaei", "affiliation": { "@type": "Organization", "name": "School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Nahid Dehghan Nayeri", "url": "https://questionsmedicales.fr/author/Nahid%20Dehghan%20Nayeri", "affiliation": { "@type": "Organization", "name": "Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Leila Sayadi", "url": "https://questionsmedicales.fr/author/Leila%20Sayadi", "affiliation": { "@type": "Organization", "name": "School of nursing & midwifery, Nursing and Midwifery Care Research Center, Tehran University of Medical Sciences, Tehran, Iran." } }, { "@type": "Person", "name": "Akram Ghobadi", "url": "https://questionsmedicales.fr/author/Akram%20Ghobadi", "affiliation": { "@type": "Organization", "name": "School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. ghobadi_a57@yahoo.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prevalence, demographics, and cognitive dysfunction among methamphetamine-dependent individuals with childhood maltreatment.", "datePublished": "2022-07-07", "url": "https://questionsmedicales.fr/article/35820226", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jpsychires.2022.07.018" } }, { "@type": "ScholarlyArticle", "name": "Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.", "datePublished": "2024-10-01", "url": "https://questionsmedicales.fr/article/39356507", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2024.36874" } }, { "@type": "ScholarlyArticle", "name": "Gut flora reflects potential risk factors for cognitive dysfunction in patients with epilepsy.", "datePublished": "2024-09-28", "url": "https://questionsmedicales.fr/article/39342383", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41043-024-00639-8" } }, { "@type": "ScholarlyArticle", "name": "Task-based profiles of language impairment and their relationship to cognitive dysfunction in Parkinson's disease.", "datePublished": "2022-10-27", "url": "https://questionsmedicales.fr/article/36301842", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0276218" } }, { "@type": "ScholarlyArticle", "name": "Distinct sleep disturbance and cognitive dysfunction profiles in oncology outpatients receiving chemotherapy.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/36066629", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00520-022-07350-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Qualité, accès, évaluation des soins de santé", "item": "https://questionsmedicales.fr/mesh/D017530" }, { "@type": "ListItem", "position": 3, "name": "Éthique", "item": "https://questionsmedicales.fr/mesh/D004989" }, { "@type": "ListItem", "position": 4, "name": "Inconduite professionnelle", "item": "https://questionsmedicales.fr/mesh/D028743" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inconduite professionnelle - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inconduite professionnelle", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inconduite professionnelle", "description": "Comment identifier l'inconduite professionnelle ?\nQuels signes indiquent une inconduite ?\nQui peut signaler une inconduite ?\nQuels outils aident au diagnostic ?\nQuelles sont les conséquences d'un diagnostic tardif ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inconduite professionnelle", "description": "Quels symptômes peuvent alerter sur une inconduite ?\nComment les patients réagissent-ils à l'inconduite ?\nQuels effets psychologiques l'inconduite a-t-elle ?\nY a-t-il des signes de stress chez le professionnel ?\nComment l'inconduite affecte-t-elle l'équipe médicale ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inconduite professionnelle", "description": "Comment prévenir l'inconduite professionnelle ?\nQuel rôle joue la supervision dans la prévention ?\nComment impliquer les patients dans la prévention ?\nQuels outils technologiques aident à la prévention ?\nQuelle est l'importance de la culture organisationnelle ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inconduite professionnelle", "description": "Quels traitements pour les victimes d'inconduite ?\nComment traiter l'inconduite chez un professionnel ?\nQuelles sanctions pour inconduite professionnelle ?\nComment réhabiliter un professionnel fautif ?\nQuels programmes de prévention existent ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inconduite professionnelle", "description": "Quelles complications peuvent résulter de l'inconduite ?\nComment l'inconduite affecte-t-elle la réputation ?\nY a-t-il des conséquences légales ?\nComment l'inconduite impacte-t-elle le personnel ?\nQuelles sont les répercussions sur les patients ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inconduite professionnelle", "description": "Quels facteurs augmentent le risque d'inconduite ?\nComment la formation influence-t-elle le risque ?\nQuel rôle joue l'environnement de travail ?\nLes antécédents personnels influencent-ils le risque ?\nComment la culture institutionnelle impacte-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Cognitive+Dysfunction&page=7#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier l'inconduite professionnelle ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite se détecte par des plaintes, des comportements inappropriés ou des violations éthiques." } }, { "@type": "Question", "name": "Quels signes indiquent une inconduite ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des comportements tels que négligence, abus de pouvoir ou fraude peuvent indiquer une inconduite." } }, { "@type": "Question", "name": "Qui peut signaler une inconduite ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Tout membre du personnel médical, patient ou tiers peut signaler une inconduite professionnelle." } }, { "@type": "Question", "name": "Quels outils aident au diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des enquêtes, des audits et des évaluations de performance aident à diagnostiquer l'inconduite." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'un diagnostic tardif ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic tardif peut aggraver les dommages aux patients et compromettre la sécurité des soins." } }, { "@type": "Question", "name": "Quels symptômes peuvent alerter sur une inconduite ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des plaintes répétées de patients, des erreurs fréquentes ou un comportement inapproprié sont des symptômes." } }, { "@type": "Question", "name": "Comment les patients réagissent-ils à l'inconduite ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent ressentir de la méfiance, de l'anxiété ou de la détresse face à l'inconduite." } }, { "@type": "Question", "name": "Quels effets psychologiques l'inconduite a-t-elle ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite peut entraîner des traumatismes psychologiques chez les patients affectés." } }, { "@type": "Question", "name": "Y a-t-il des signes de stress chez le professionnel ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Un professionnel en inconduite peut montrer des signes de stress, d'irritabilité ou d'isolement." } }, { "@type": "Question", "name": "Comment l'inconduite affecte-t-elle l'équipe médicale ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut créer des tensions, diminuer la confiance et affecter la collaboration au sein de l'équipe." } }, { "@type": "Question", "name": "Comment prévenir l'inconduite professionnelle ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des formations éthiques, des codes de conduite et un environnement de travail sain." } }, { "@type": "Question", "name": "Quel rôle joue la supervision dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une supervision adéquate permet de détecter et de corriger les comportements inappropriés rapidement." } }, { "@type": "Question", "name": "Comment impliquer les patients dans la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent être formés à reconnaître et signaler des comportements inappropriés." } }, { "@type": "Question", "name": "Quels outils technologiques aident à la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de signalement en ligne et des applications de suivi des comportements peuvent aider." } }, { "@type": "Question", "name": "Quelle est l'importance de la culture organisationnelle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une culture organisationnelle positive favorise l'éthique et réduit les risques d'inconduite." } }, { "@type": "Question", "name": "Quels traitements pour les victimes d'inconduite ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les victimes peuvent bénéficier de thérapies psychologiques et de soutien émotionnel." } }, { "@type": "Question", "name": "Comment traiter l'inconduite chez un professionnel ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures disciplinaires, des formations et un suivi psychologique peuvent être nécessaires." } }, { "@type": "Question", "name": "Quelles sanctions pour inconduite professionnelle ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les sanctions peuvent inclure des avertissements, des suspensions ou des radiations de l'ordre." } }, { "@type": "Question", "name": "Comment réhabiliter un professionnel fautif ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La réhabilitation peut passer par des formations, du mentorat et un suivi régulier." } }, { "@type": "Question", "name": "Quels programmes de prévention existent ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des programmes de formation éthique et de sensibilisation sont mis en place pour prévenir l'inconduite." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de l'inconduite ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages physiques, psychologiques et une perte de confiance dans le système de santé." } }, { "@type": "Question", "name": "Comment l'inconduite affecte-t-elle la réputation ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'inconduite peut gravement nuire à la réputation du professionnel et de l'établissement de santé." } }, { "@type": "Question", "name": "Y a-t-il des conséquences légales ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inconduite peut entraîner des poursuites judiciaires et des sanctions pénales." } }, { "@type": "Question", "name": "Comment l'inconduite impacte-t-elle le personnel ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut créer un environnement de travail toxique, affectant le moral et la productivité du personnel." } }, { "@type": "Question", "name": "Quelles sont les répercussions sur les patients ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent subir des erreurs médicales, des abus ou une détérioration de leur état de santé." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'inconduite ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, la surcharge de travail et un manque de supervision sont des facteurs de risque importants." } }, { "@type": "Question", "name": "Comment la formation influence-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Une formation insuffisante peut accroître le risque d'inconduite en diminuant la sensibilisation éthique." } }, { "@type": "Question", "name": "Quel rôle joue l'environnement de travail ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement de travail toxique ou compétitif peut favoriser l'inconduite professionnelle." } }, { "@type": "Question", "name": "Les antécédents personnels influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de comportements inappropriés ou de problèmes psychologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Comment la culture institutionnelle impacte-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Une culture institutionnelle laxiste envers l'éthique peut accroître le risque d'inconduite." } } ] } ] }

Sources (10000 au total)

Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.

Neurologic post-COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are... To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction.... A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently... Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label li... Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the sco... Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two par... In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lit... ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297....

Gut flora reflects potential risk factors for cognitive dysfunction in patients with epilepsy.

This cross-sectional study aims to analyze the differences in gut flora between patients with epilepsy with and without cognitive impairment and normal subjects.... One hundred patients with epilepsy who came to our hospital from 2020.12 to 2022.12 (epilepsy group) were selected, and another 100 family members of the patients were selected as the control group (c... There were more significant differences in the structure and composition of the gut flora between patients in the epilepsy group and the control group, but no significant differences in diversity anal... There was an imbalance in the gut flora of patients with epilepsy compared to healthy controls. The gut flora of patients with epilepsy with cognitive dysfunction differs significantly from that of pa...

Task-based profiles of language impairment and their relationship to cognitive dysfunction in Parkinson's disease.

Parkinson's Disease (PD) is associated with both motor and non-motor problems, such as cognitive impairment. Particular focus in this area has been on the relationship between language impairment and ... 22 non-demented people with PD (PwPD) and 22 healthy control participants performed a range of cognitive and language tasks. Cognitive tasks included a screening assessment in addition to tests for se... The study highlighted impaired ability in set-shifting and letter fluency in the executive function tasks, and a higher rate of grammatical and lexical errors across all language tasks in the PD group... Our results suggest that there is a link between executive function and language performance, but that this is task dependent in non-demented PwPD. This has implications for the management of language...

Distinct sleep disturbance and cognitive dysfunction profiles in oncology outpatients receiving chemotherapy.

Sleep disturbance and cancer-related cognitive impairment (CRCI) are two of the most common symptoms reported by patients undergoing chemotherapy. Less is known about how these symptoms co-occur and t... A total of 1,333 oncology outpatients receiving chemotherapy completed self-report questionnaires on sleep disturbance and cognitive dysfunction six times over two cycles of chemotherapy. Latent profi... Two distinct profiles were identified (i.e., Low = low levels of both sleep disturbance and cognitive dysfunction (53.5%); High = high levels of both sleep disturbance and cognitive dysfunction (45.5%... Almost half of the patients undergoing chemotherapy experienced clinically meaningful levels of both symptoms. Of note, sleep disturbance is frequently overlooked by both clinicians and patients. Clin...

Serum neurofilament light reflects cognitive dysfunctions in children with obstructive sleep apnea.

In children, obstructive sleep apnea (OSA) can cause cognitive dysfunctions. Amyloid-beta and tau are elevated in OSA. Neurofilament light (NfL) is a marker of neuro-axonal damage, but there are no re... This retrospective case-control study included children diagnosed with adenoid tonsil hypertrophy from July 2017 to September 2019 at the Second Affiliated Hospital of Xi'an Jiaotong University. Corre... Fifty-six OSA and 49 non-OSA children were included. The serum NfL levels were higher in the OSA group (31.68 (27.29-36.07) pg/ml) than in the non-OSA group (19.13 (17.32-20.95) pg/ml) (P < 0.001). Mo... Serum NfL levels are associated with the severity of cognitive dysfunctions in children diagnosed with adenoid tonsil hypertrophy and might be a candidate noninvasive, objective marker to identify cog...

Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson's disease patients.

Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and Neurofilament light chain (NfL) are associated with Lewy body formation, Lewy bodies are the main pathological feature of Parkinson's disease (PD).... There were significant differences in UCH-L1 and NfL levels among PD patients with normal cognitive function (PD-CN), PD patients with mild cognitive impairment (PD-MCI), and PD-dementia patients (PDD... Decreased UCH-L1 levels and elevated NfL levels in the blood are associated with cognitive dysfunction in PD; thus, these proteins are potential biomarkers for the diagnosis of cognitive dysfunction i...

Development of criteria for cognitive dysfunction in post-COVID syndrome: the IC-CoDi-COVID approach.

We aimed to develop objective criteria for cognitive dysfunction associated with the post-COVID syndrome.... Four hundred and four patients with post-COVID syndrome from two centers were evaluated with comprehensive neuropsychological batteries. The International Classification for Cognitive Disorders in Epi... According to the developed criteria, 41.2% and 17.3% of the sample were classified as having at least one cognitive domain impaired using -1 and -1.5 standard deviations as cutoff points. Attention/pr... We propose a harmonization of the criteria to define and classify cognitive impairment in the post-COVID syndrome. These criteria may be extrapolated to other neuropsychological batteries and settings...

Retinal Thickness Associates with Cognition Dysfunction in Young Adult with Type 1 Diabetes in Taiwan.

Several factors could affect the cognitive dysfunction in patients with type 1 diabetes (T1D).... To report the characteristic of cognitive dysfunction in T1D and find its association with the retinal thickness.... We recruited one hundred and seven patients with T1D in our study.... Detailed clinical and demographic factors and Cambridge Automated Neuropsychological Test Battery (CANTAB) were performed in all participants. The age at onset>5 years old and ≤5 years old groups was ... The median age of T1D was 24.9 years old and 57 participants were women. The median age at onset was 7.4 years old, and mean disease duration was 17.2 years. After adjusting off multiple covariates by... Our results suggest that age at onset and glycemic control had significant impacts on different cognitive domains in T1D. The CRT had a significant correlation with sustained attention, which could be...

Effects of comorbid posttraumatic stress disorder on cognitive dysfunction in Chinese male methamphetamine patients.

Cognitive dysfunction and posttraumatic stress disorder (PTSD) are common in methamphetamine patients. However, few studies have investigated the cognitive performance of methamphetamine patients with... We analyzed 464 methamphetamine patients and 156 healthy volunteers. The PTSD Screening Scale (PCL-5) was used to assess PTSD and the Repeatable Battery for the Assessment of Neuropsychological Status... Compared with healthy controls, methamphetamine patients had more cognitive dysfunction in immediate memory, visuospatial/constructional, language, attention and delayed memory. Moreover, methamphetam... Our results indicate that methamphetamine patients without PTSD have poorer cognitive dysfunction than those with PTSD. Some demographic and PTSD symptom clusters are protective or risk factors for co...